The Recombinant Polyclonal Drug Candidate GIGA-2339 for Hepatitis B Treatment

We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the groundbreaking advancements of GIGA-2339, the first recombinant polyclonal drug candidate in development for the treatment of hepatitis B virus (HBV) infection. This innovative therapy has the potential to transform HBV treatment by addressing the diverse variants of the virus and offering hope for the first functional cure. (Friday, Dec 20, 3 PM ET) Click here to join webinar on LinkedIn:>>>

Beyond its implications for HBV, GIGA-2339 underscores the potential of GigaGen’s next-generation platform to revolutionize antibody therapeutics across infectious diseases and oncology. Join us as we explore how this pioneering approach is reshaping the landscape of drug development and advancing patient care.

Some of the main topics in this interview include:

• The overview of the global burden of HBV infection and its serious consequences for healthcare systems worldwide
• GIGA-2339 is the first recombinant polyclonal drug candidate for HBV. How does its mechanism of action differ from existing HBV treatments, and what makes it potentially more effective?
• Could you elaborate on the primary objectives of the Phase 1 trial for GIGA-2339, and what specific outcomes you are hoping to achieve in terms of safety and tolerability?
• GIGA-2339 has shown promise in preclinical models by activating the immune response. Can you explain how this activation contributes to the potential for a functional cure?
• GigaGen’s platform enables the creation of recombinant polyclonal therapies. How does this technology differ from traditional monoclonal antibody development, and what are its broader implications for treating infectious diseases?
• Aside from GIGA-2339, could you provide an overview of other promising candidates in GigaGen’s pipeline? Are there plans to expand the recombinant polyclonal antibody platform to other infectious diseases or therapeutic areas, including the development of GIGA-564 for oncology?